Guidelines and evidence
Where this site's information comes from
Each entry states what can and cannot be concluded from its source. TanyaKanker does not reproduce guideline text or claim that this site is equivalent to a clinical guideline.
Guidelines and reference sources
- National Cancer InstituteContinually updatedPublic reference
NCI PDQ treatment summaries
Evidence-based treatment summaries published by the NCI and updated regularly for many cancer types.
Used to verify that treatment categories described by TanyaKanker are covered in public sources. We do not reproduce the source text.
Open official source - National Cancer InstituteContinually updatedPublic reference
NCI: biomarker and molecular testing overview
An institutional overview of molecular biomarker testing and its role in treatment selection.
Used as a conceptual reference for biomarker testing, not as a source for doses or regimens.
Open official source - World Health OrganizationContinually updatedPublic reference
WHO cancer fact sheets
WHO cancer fact sheets describing disease burden and prevention.
Used for global and regional disease-burden context. We do not present country-specific figures without a direct citation.
Open official source - International Agency for Research on CancerContinuously updated registry estimatesPublic reference
IARC Global Cancer Observatory
A database of estimated cancer incidence and mortality by country and region.
An official source when incidence figures are needed. We deliberately do not display figures without linking to the original table.
Open official source - US National Library of MedicineLive registryPublic reference
ClinicalTrials.gov registry
The public clinical-study registry that supplies TanyaKanker clinical-trial data.
Registry facts such as identifier, phase, status, and location come from this source. International-patient access, cost, and site readiness do not come from the registry and are always marked unverified.
Open official source - European Society for Medical OncologyPer disease, updated by the societyPublic reference
ESMO clinical practice guidelines
Disease-specific clinical practice guidelines published by the European oncology society.
Used to check the general direction of clinical discussion. We do not reproduce guideline text or interpret it as advice for an individual.
Open official source - American Society of Clinical OncologyPer topic, updated by the societyPublic reference
ASCO guidelines and guideline updates
Guidelines and updates from the American oncology society across many clinical topics.
Used as a reference for the direction of discussion, not as a source for doses or individual treatment decisions.
Open official source - Kementerian Kesehatan Republik IndonesiaPer regulation and programmePublic reference
Indonesian Ministry of Health: cancer guidance and services
National policy and guideline references, including the context of cancer referral and screening services in Indonesia.
Used for the context of Indonesian services and referrals, including public referral-facility lists. TanyaKanker does not claim a partnership with any facility.
Open official source
Evidence notes by claim
Each note states which claims the source can support and which it cannot.
- InstitutionUS National Library of Medicine - 2026
What recruitment status means in a registry
A registry reports study status, not site readiness or acceptance of patients from outside the study country.
Supports the separation of three statuses on each study card. The registry does not contain international-access information.
Citation: ClinicalTrials.gov study records: overall status field
Source - InstitutionNational Cancer Institute - 2026
Purpose of molecular biomarker testing
Biomarker testing looks for tumour features that may affect which treatment categories are discussed.
Used to explain the concept, not to determine whether a treatment fits an individual.
Citation: NCI precision medicine overview
Source - InstitutionNational Cancer Institute - 2026
PD-L1 scoring differs by cancer type
PD-L1 scores are reported under different rules for different cancer types and cannot be transferred between them.
Supports the warning shown on PD-L1 biomarker pages.
Citation: NCI dictionary: PD-L1 and tumour proportion score
Source - InstitutionNational Cancer Institute - 2026
Meaning of MSI-high and dMMR
MSI-high and dMMR describe impaired DNA repair that may affect which immunotherapy categories are discussed.
Used to explain the concept and the potential need for genetic counselling in selected cases.
Citation: NCI dictionary: microsatellite instability and mismatch repair
Source - InstitutionNational Cancer Institute - 2026
Special monitoring for cell therapy
Cell therapy requires close monitoring because reactions such as cytokine release syndrome can occur.
Supports the monitoring section on CAR-T pages. It is not a protocol for managing those reactions.
Citation: NCI dictionary: CAR T-cell therapy and cytokine release syndrome
Source - InstitutionNational Cancer Institute - 2026
Clinical-trial phases
Clinical-trial phases describe the study purpose, from safety assessment to comparison of benefit.
Used in the guide to understanding clinical trials without making an individual eligibility determination.
Citation: NCI: what are clinical trials
Source - InstitutionWorld Health Organization - 2026
Global and regional cancer burden
A global overview of cancer burden, risk factors, and control strategies.
We do not display specific figures without linking to the source table because figures must be read in the context of year and method.
Citation: WHO cancer fact sheet
Source - InstitutionKementerian Kesehatan Republik Indonesia - 2026
Indonesian referral-service context
Public information about national and regional referral services in Indonesia.
Used to identify referral facilities as public references. It does not imply a partnership, price, or guarantee of acceptance.
Citation: Kementerian Kesehatan RI: layanan rujukan
Source - InstitutionNational Cancer Institute - 2026
Mechanisms of resistance to EGFR inhibitors
After progression on an EGFR inhibitor, repeat molecular testing is commonly considered to look for resistance mechanisms such as a secondary EGFR alteration or MET amplification.
Used to explain resistance and the reason for repeat testing. This source is not used to recommend a regimen; treatment choices remain with the treating doctor.
Citation: NCI precision medicine overview; ESMO lung cancer guidelines
Source
Not yet available
No entry has completed doctor review yet. The reviewer's name, review date, and conflict-of-interest note will appear here after the review process is complete.
How we use sources
Sources are used to verify that a category is discussed in public literature. We do not reproduce text, interpret guidelines as advice for an individual, or display figures without linking to the original table.
Open patient guides